Gilad Yahalom, Eden Atlan, Amir Janah, Melania Dominko, Ilana Israel, Gustavo Rajz, Stefan Mausbach, Roni Eichel
OBJECTIVES: This is a case series and a review of the literature of therapeutic outcomes of botulinum toxin (BT) injections for anterocollis. METHODS: Data collected included gender, age, age at onset, muscles targeted, and doses injected. Routine forms were filled out during each visit: Patient Global Impression of Change, Clinician Global Impression of Severity, Tsui scale. The effect duration and side effects (SEs) of the previous treatment were noted. RESULTS: We described 4 patients (3 men, 13 visits) with anterocollis, as primary postural abnormality of the neck, emphasizing the therapeutic response to BT injection...
March 13, 2023: Clinical Neuropharmacology
Yojiro Umezaki, Haruhiko Motomura, Rui Egashira, Akira Toyofuku, Toru Naito
OBJECTIVES: Oral cenesthopathy is an uncomfortable and bizarre oral sensation without corresponding organic findings. Although some treatment options, including antidepressants and antipsychotic drugs, have been reported to be effective, the condition remains refractory. Here, we report a case of oral cenesthopathy treated with brexpiprazole, a recently approved D2 partial agonist. METHODS AND RESULTS: A 57-year-old woman presented with a complained of softened incisors...
March 10, 2023: Clinical Neuropharmacology
Charles Springer, Robert Rodgers, Gina Vivino, Saritha Attanagoda, Charles Dylan Miks
Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time she developed delusions. We also discuss the use of aripiprazole to mitigate the psychotic symptoms, while maintaining the efficacy of cabergoline treatment.
March 7, 2023: Clinical Neuropharmacology
Brendan Perreault, Nikki Hammond, Panayotis K Thanos
OBJECTIVE: Research points to exercise having a positive effect in fighting relapse and use of drugs of abuse. Through conducting this research, differences have been observed in the effects of exercise on drug abuse between sexes. Many of the studies found that exercise tends to cause a more profound effect in blocking drug relapse or reinstatement in males when compared with females. METHODS: Our hypothesis is that these differences in response to drugs of abuse after an exercise regimen could in part be attributed to variations in testosterone levels between males and females...
March 7, 2023: Clinical Neuropharmacology
Yaqian Zhang, Feng Zhou, Huiqing Li, Junjie Lei, Zhihuai Mo, Guangrong Li, Junfeng Wang
OBJECTIVES: Intravenous thrombolysis and mechanical endovascular thrombectomy are recommended for patients whose stroke onsets are within the first 6 hours; however, patients beyond this time window have very limited options. Dl-3-n-butylphthalide (NBP) and human urinary kallidinogenase (HUK) have shown potential clinical benefits in the treatment of acute ischemic stroke (AIS) patients. This research aims to investigate the efficacy and safety of NBP combined with HUK in the treatment of ischemic stroke patients...
February 16, 2023: Clinical Neuropharmacology
Joseph H Friedman
No abstract text is available yet for this article.
February 16, 2023: Clinical Neuropharmacology
Fereshteh Shakibaei, Danial Jelvani
OBJECTIVES: The present research aimed to evaluate the effect of adding l-carnitine to risperidone in treating children and adolescents with autism spectrum disorder (ASD). METHODS: In this randomized controlled clinical trial study, 50 ASD children and adolescents were divided into 2 groups: those receiving l-carnitine and risperidone (n = 25) and those receiving placebo and risperidone (n = 25). Treatment continued for 8 weeks, and participants were assessed at the beginning of the study, in the fourth and eighth weeks, by the Aberrant Behavior Checklist (ABC)...
February 4, 2023: Clinical Neuropharmacology
Amber Patt, Haley Fox, Lauren Wells, Jillian Theobald, Ryan Feldman
OBJECTIVE: Phenibut is a widely available gamma-aminobutyric acid B receptor agonist. When taken chronically, phenibut causes dependence and subsequent withdrawal if stopped. Baclofen, a gamma-aminobutyric acid B receptor agonist structurally related to phenibut, has been used to manage phenibut withdrawal (PW), although baclofen doses for PW are not well defined and may exceed Food and Drug Administration-approved doses. Little data described outcomes from baclofen use. METHODS: This case details a patient who experienced a seizure while on baclofen 10 mg thrice daily as monotherapy for PW and highlights a potential risk of underdosing baclofen as monotherapy in the management of PW...
February 4, 2023: Clinical Neuropharmacology
Robert A Hauser, Peter A LeWitt, Cheryl H Waters, Donald G Grosset, Burkhard Blank
Oral levodopa is the most effective treatment for Parkinson disease, but OFF periods emerge over time. Gastrointestinal dysfunction and food effects impact levodopa absorption, contributing to unpredictable control of OFF periods. Inhaled levodopa powder (Inbrija) is approved for on-demand treatment of OFF periods in patients receiving oral levodopa-dopa decarboxylase inhibitors. The 84-mg dose is administered via a breath-actuated inhaler. It provides pulmonary delivery of levodopa to the systemic circulation and is taken when a patient has an OFF period in between doses of regular oral levodopa medication...
January 30, 2023: Clinical Neuropharmacology
Lola Díaz-Feliz, Cici Feliz-Feliz, Javier Del Val, Marta Ruiz-López, Pedro J García-Ruiz
OBJECTIVES: The aim of this study was to assess the safety and efficacy of perampanel in patients with refractory essential tremor (ET). METHODS: We recruited patients from our movement disorders clinic with the diagnosis of severe refractory ET, and perampanel 4 mg at night was initiated.Assessments were conducted at baseline and after 1 month of treatment with perampanel 4 mg/d. Details about tolerance and effectiveness were collected. Clinical evaluation was conducted with the Fahn-Tolosa-Marín scale, and statistical analysis was carried out with Wilcoxon matched pairs signed rank test...
January 25, 2023: Clinical Neuropharmacology
Peter LeWitt, Grace S Liang, C Warren Olanow, Karl D Kieburtz, Roland Jimenez, Kurt Olson, Olga Klepitskaya, Gordon Loewen
OBJECTIVES: Levodopa (LD) administered with dopa decarboxylase inhibitor is predominantly metabolized in the periphery by catechol-O-methyltransferase (COMT) to 3-O-methyldopa (3-OMD). Catechol-O-methyltransferase inhibition can improve treatment outcomes by decreasing variability in circulating LD concentrations. Opicapone is a once-daily COMT inhibitor approved in the US adjunctive to carbidopa (CD)/LD in patients with Parkinson disease experiencing "OFF" episodes. This study aimed to evaluate the pharmacokinetics and pharmacodynamics of once-daily opicapone 50 mg adjunctive to CD/LD in patients with stable Parkinson disease...
January 23, 2023: Clinical Neuropharmacology
Saliha Baykal, Caner Mutlu
OBJECTIVES: This report discusses the emergence, clinical appearance, and treatment of the rare entity Capgras syndrome (CS) in an adolescent diagnosed with autism. METHODS: After a brief introduction to the CS, we conduct a detailed description of the case and review, after a search on the PubMed database, the known pathophysiology, psychiatric disorders associated with the onset of this syndrome, and the management of CS. RESULTS: Capgras syndrome generally emerges during the course of delusional disorder, schizophrenia, or mood disorders, and for reasons such as neurological, infectious, or endocrinological diseases, drug intoxications, or deprivation...
December 27, 2022: Clinical Neuropharmacology
Ozge Gonul Oner, Hasan Can Gudek, Ozdem Erturk Cetin, Serkan Demir
OBJECTIVE: Botulinum toxin type A is widely used for the treatment of spasticity, focal dystonia, hemifacial spasm, hyperhidrosis, strabismus, chronic migraine, and also cosmetic purposes. Therapeutic use is commonly effective and safe. However, if toxin enters the vascular space and gets through to peripheral cholinergic nerve terminals, it may lead to iatrogenic botulism. METHOD: We presented a patient who is diagnosed as iatrogenic botulism and treated with antitoxin at the 15th day of the exposure...
December 27, 2022: Clinical Neuropharmacology
Sara Otero Torres, Roser Juvany Roig, Mercè Falip Centellas, Miriam Casellas Gibert, Mónica Estopiñá Antolí, Raül Rigo Bonnin, Jacint Xavier Sala-Padro, Ramón Jódar Massanés
OBJECTIVES: The reference range for lacosamide (LCM) has been updated from 1 to 10 mg/L to 10 to 20 mg/L. Historically, LCM range was defined from trough-level measurements, but the newer ranges were obtained from peak-level measurements. The purpose of the study was to evaluate the relationship between LCM plasma levels higher than 10 mg/L and the incidence of adverse effects. METHODS: This was a single-center, retrospective, observational study of adult outpatients with epilepsy who were prescribed LCM and had LCM serum concentrations (LCM-SCs) >10 mg/L on drug-fasting samples, measured from June 2017 to December 2020...
December 27, 2022: Clinical Neuropharmacology
Jinrong Lian, Jiahe Wang, Xiang Li, Siyuan Yang, Hang Li, Yi Zhong, Heng Gao, Gang Chen
OBJECTIVE: The aim of this study was to assess the efficacy of different dosage regimens of tanezumab among individuals living with chronic low back pain (CLBP). METHODS: PubMed, Embase, The Cochrane Library, and other databases were searched from inception until August 2021. Randomized controlled trials investigating the efficacy and safety of tanezumab in individuals with CLBP were included. Data were extracted independently by 2 investigators and assessed the study quality by the Cochrane risk-of-bias tool...
December 22, 2022: Clinical Neuropharmacology
Geetesh Verma, Deepaneeta Sarmah, Aishika Datta, Avirag Goswami, Nikita Rana, Harpreet Kaur, Anupom Borah, Sudhir Shah, Pallab Bhattacharya
OBJECTIVES: The present review describes stroke pathophysiology in brief and discusses the spectrum of available treatments with different promising interventions that are in clinical settings or are in clinical trials. METHODS: Relevant articles were searched using Google Scholar, Cochrane Library, and PubMed. Keywords for the search included ischemic stroke, mechanisms, stroke interventions, clinical trials, and stem cell therapy. RESULTS AND CONCLUSION: Stroke accounts to a high burden of mortality and morbidity around the globe...
December 14, 2022: Clinical Neuropharmacology
Qiang Deng, Sihong Tao, Hui Huang, Qikun Lv, Wei Wang
INTRODUCTION: Chloroquine supplementation may show some potential in improving the efficacy for glioblastoma, and this meta-analysis aimed to identify the efficacy of chloroquine supplementation for patients with glioblastoma. METHODS: Several databases including PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases have been systematically searched through August 2022, and we included randomized controlled trials assessing the efficacy of chloroquine supplementation for glioblastoma...
November 21, 2022: Clinical Neuropharmacology
Odete Nombora, Ana Samico, Ângela Venâncio
BACKGROUND: Bipolar disorder is a complex psychiatric disorder where long-term treatment is crucial to maintain stabilization. Although largely well tolerated, lithium has a wide spectrum of adverse effects in different organs and seems to also cause taste and smell disorders, which remain rare and not largely described. We aim to present a rare case of hyposmia and dysgeusia secondary to lithium treatment in a bipolar patient and also conduct a review on these rare lithium adverse effects...
November 9, 2022: Clinical Neuropharmacology
Nurşah Yeniay Süt, Miraç Yıldırım, Ömer Bektaş, Tanıl Kendirli, Serap Teber
OBJECTIVE: Lance-Adams syndrome is a rare but devastating disorder characterized by rest, action, and stimulus-sensitive myoclonus after cardiorespiratory arrest. We aimed to present a case of multidrug-resistant Lance-Adams syndrome that was successfully treated with oral phenobarbital therapy. METHOD AND RESULTS: We report a previously healthy 11-year, 6-month-old boy was referred to our pediatric intensive care unit because of severe hypoxic ischemic brain injury due to sudden cardiorespiratory arrest...
November 9, 2022: Clinical Neuropharmacology
Masaru Nakamura, Takahiko Nagamine
INTRODUCTION: Clozapine-induced fever is frequently documented in the early stages of administration. Fever during clozapine treatment often presents a clinical challenge, because there are no established guideline to decide when fever is the adverse effect. Although the etiology of clozapine-induced fevers remains unknown, evidence has suggested that fever may develop secondarily to a generalized inflammatory response as a manifestation of the immune-modulating effects of clozapine. CASE PRESENTATION: We presented a 59-year-old male patient with a treatment-resistant schizophrenia, who was introduced clozapine for the first time...
November 2022: Clinical Neuropharmacology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.